B. Riley Wealth Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

B. Riley Wealth Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,423	Closed	-$345K	–	522
2020 Q1	$345K	Buy	7,423 +142	+2%	+$7.41K	0.04%	331
2019 Q4	$407K	Sell	7,281 -409	-5%	-$21.3K	0.06%	238
2019 Q3	$264K	Buy	7,690 +142	+2%	+$7.28K	0.05%	300
2019 Q2	$404	Hold	7,548	–	–	0.06%	239
2019 Q1	$417K	Hold	7,548	–	–	0.07%	235
2018 Q4	$355K	Buy	+7,548	New	+$388K	0.07%	221
2014 Q3	–	Sell	-610	Closed	-$26K	–	1139
2014 Q2	$26K	Buy	+610	New	+$24.7K	0.02%	597

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

ACM

Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

B. Riley Wealth Management's PBE Position: Q2 2020 in Review

B. Riley Wealth Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2020, closing a stake of 7,423 shares — an estimated $345K sold.

B. Riley Wealth Management first reported a position in PBE in Q2 2014 and held it in 7 quarters. The position peaked at $417K in Q1 2019. 77 funds tracked by Wall St. Rank hold PBE as of Q2 2020.

B. Riley Wealth Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2020 after selling out during the quarter.
B. Riley Wealth Management sold 7,423 Invesco Biotechnology & Genome ETF shares in Q2 2020, an estimated $345K.
B. Riley Wealth Management first reported a position in Invesco Biotechnology & Genome ETF in Q2 2014 and held it in 7 quarters.
B. Riley Wealth Management's Invesco Biotechnology & Genome ETF position peaked at $417K in Q1 2019.
77 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2020.

Based on B. Riley Wealth Management's 13F filing for Q2 2020, filed 17 Aug 2020.